The potential of biotechnology to improve the quality of life of patients with renal failure.
Bloembergen
W E
WE
Department of Medicine, University of Western Ontario, London, Canada.
Laupacis
A
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001709:Biotechnology; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D016853:Muromonab-CD3; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D016853:Muromonab-CD3; D011994:Recombinant Proteins; D004921:Erythropoietin